Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 28;13(6):804.
doi: 10.3390/pharmaceutics13060804.

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

Ewelina Juszczyk  1 , Kamil Kisło  1 , Paweł Żero  1 , Ewa Tratkiewicz  1 , Maciej Wieczorek  1 , Jadwiga Paszkowska  2 , Grzegorz Banach  2 , Marcela Wiater  2 , Dagmara Hoc  2 , Grzegorz Garbacz  2   3 , Jaroslaw Sczodrok  3 , Dorota Danielak  4
Affiliations

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

Ewelina Juszczyk et al. Pharmaceutics. .

Abstract

Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy.

Keywords: GPR40 agonist; biorelevant dissolution testing; first in human clinical trials; simulation of gastrointestinal passage; stress test device; sustained-release tablets.

PubMed Disclaimer

Conflict of interest statement

This article reflects the authors’ view only. Neither the Research Executive Agency nor the Polish Ministry of Science and Higher Education may be held responsible for the use which may be made of the information contained therein. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
The analysis workflow.
Figure 2
Figure 2
The dissolution profiles obtained in the USP II paddle apparatus in phosphate buffer pH = 6.8. Profiles for prototypes (Panels A and B) are presented as means from n = 3 replicates, while final formulations of hardness 185–225 N (Panel C) are presented as means from n = 6 replicates, and standard deviations as error bars.
Figure 3
Figure 3
Mean deformation profiles obtained for the final formulations of hardness 185–225 N (n = 3) with standard deviations presented as shaded areas.
Figure 4
Figure 4
Comparison of dissolution profiles obtained in biorelevant media in the StressTest device under simulated standard fasted and fed conditions. (A,B) Dissolution profiles of the prototypes. (C,D) Dissolution profiles of the final formulations of different hardnesses, containing 5, 30, and 120 mg of the API. The data are presented as means of the cumulative amount of the drug released in percent (n = 6 for final, J and K batches, n = 3 for batches H and I under simulated fasted conditions, n = 2 for batches H and I under simulated fed conditions) with standard deviations presented as shaded areas.
Figure 5
Figure 5
Comparison of dissolution profiles of the final formulations (hardness 185–225 N) containing 5, 30, and 120 mg API, obtained in biorelevant media in the StressTest device under simulated modified fasted and fed conditions. The data are presented as means of the cumulative amount of the drug released in percent (n = 6, n = 4 for the “Increased agitation” protocol under simulated fed conditions) with standard deviations presented as shaded areas.
See this image and copyright information in PMC

References

    1. Levy J., Cobas R.A., Gomes M.B. Assessment of efficacy and tolerability of once- daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2010;2:16. doi: 10.1186/1758-5996-2-16. - DOI - PMC - PubMed
    1. Donnelly L.A., Morris A.D., Pearson E.R. Adherence in patients transferred from immediate release metformin to a sustained release formulation: A population-based study. DiabetesObes. Metab. 2009;11:338–342. doi: 10.1111/j.1463-1326.2008.00973.x. - DOI - PubMed
    1. Lu C., Chang C., Chuang L., Wang C.Y., Jiang Y.D., Wu H.P. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes Obes. Metab. 2006;8:184–191. doi: 10.1111/j.1463-1326.2005.00501.x. - DOI - PubMed
    1. Wang L., Sun X., Du L., Yuan Q., Li H., Tian H., Li Y. Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J. Evid. Based Med. 2011;4:232–241. doi: 10.1111/j.1756-5391.2011.01158.x. - DOI - PubMed
    1. Van Dijk F., Teekamp N., Beljaars L., Post E., Zuidema J., Steendam R., Kim Y.O., Frijlink H.W., Schuppan D., Poelstra K., et al. Pharmacokinetics of a sustained release formulation of PDGF β -receptor directed carrier proteins to target the fi brotic liver. J. Control. Release. 2018;269:258–265. doi: 10.1016/j.jconrel.2017.11.029. - DOI - PubMed